Neuren Pharmaceuticals: From New Zealand roots to ASX stardom

Neuren Pharmaceuticals: From New Zealand roots to ASX stardom
Neuren's Melbourne-based CEO Jon Pilcher credits the pharmaceutical firm's breakthrough medications to NZ research. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
It was the best-performing stock on the ASX in 2023, has a market cap of about $2.2 billion, doesn’t have an office, and was founded in New Zealand. Neuren Pharmaceutical’s medication trofinetide became the first US Food and Drug Administration (FDA) approved treatment for the disabling neurological disorder Rett syndrome in March 2023. Rett syndrome is rare, “profoundly debilitating”, and mostly affects female children. It leads to developmental delays and sometimes regressions as the child ages. Neuren s...

More Markets

‘I want to get my life back’: Ebos’ John Cullity
Markets

‘I want to get my life back’: Ebos’ John Cullity

He's ‘had a great run’, but the Ebos CEO says it’s time to recalibrate and reset.

Fletcher Building cuts more than 500 jobs
Infrastructure

Fletcher Building cuts more than 500 jobs

Fletcher is overachieving in cost cutting, managing director Andrew Reding says.

Westpac looks seaward to boost NZ's economy
Primary Sector

Westpac looks seaward to boost NZ's economy

A senior scientist says less red tape could transform the aquaculture industry.

NZ sharemarket dips as interest rates cut
Markets Market Close

NZ sharemarket dips as interest rates cut

The S&P/NZX 50 Index closed at 13,033.36, down 17.76 points or 0.14%.

Staff reporters 19 Feb 2025